Can AI offer disruptive opportunities for pharma?

市場監測

  • 奧地利,
  • 比利時,
  • 中國,
  • 法國,
  • 德國,
  • 印度,
  • 意大利,
  • 日本,
  • 墨西哥,
  • 荷蘭,
  • 波蘭,
  • 葡萄牙,
  • 斯洛文尼亞,
  • 西班牙,
  • 瑞典,
  • 瑞士,
  • 美國,
  • 英國
  • 化學/制藥

2023年09月05日

Atradius Pharmaceuticals Sector Experts share their insights and opinions on how AI will impact the industry.

Artificial Intelligence (AI), Big Data and machine learning are already commonly used by businesses, especially for improving productivity for automated tasks in manufacturing and for extracting patterns amongst large volumes of data.

Although initially slow to gain momentum, research indicates that AI in the global healthcare sector is also now accelerating. AI investment in the industry was around USD 15 billion in 2022 and is expected to reach more than USD 187 billion by 2030.

But are such growth predictions consistent across markets or regions? We asked our Pharmaceuticals Experts from Asia-Pacific, Europe and the Americas for their insights into usage and opportunities presented by AI and Big Date in their regions.

Among the feedback they shared Judy Ji, Atradius Pharmaceuticals Expert for the Asia-Pacific, noted the growth of new opportunities that AI presents in her region. She points out that both external investors and new players can springboard off AI into a market they have traditionally not worked in before.

However, the growth of AI also poses risks to the industry. For example, our Sector Expert for Europe, Rubén del Río Hernández, asks whether smaller pharma businesses are equipped to compete with large tech firms.

Our Sector Expert for the Americas, Patrick Scardina, agrees with this existential question. He cautions pharma companies can ill afford to be left behind and suggests many will seek to invest or partner with technology firms in order to survive.

In addition to competition and collaboration, the sector experts also explored issues such as the regulatory hurdles concerning AI in the industry and further risks and opportunities presented by the increased use of AI in the pharmaceuticals industry.

 

相關資料

免責聲明

Each publication available on or from our websites, such as, but not limited to webpages, reports, articles, publications, tips and helpful content, trading briefs, infographics, videos (each a “Publication”) is provided for information purposes only and is not intended as a recommendation or advice as to particular transactions, investments or strategies in any way to any reader. Readers must make their own independent decisions, commercial or otherwise, regarding the information provided. While we have made every attempt to ensure that the information contained in any Publication has been obtained from reliable sources, Atradius is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in any Publication is provided ’as is’, with no guarantee of completeness, accuracy, timeliness or of the results obtained from its use, and without warranty of any kind, express or implied. In no event will Atradius, its related partnerships or corporations, or the partners, agents or employees thereof, be liable to you or anyone else for any decision made or action taken in reliance on the information in any Publication, or for any loss of opportunity, loss of profit, loss of production, loss of business or indirect losses, special or similar damages of any kind, even if advised of the possibility of such losses or damages.